Skip to main content
In stock|Targeted Therapy

Acalabrutinib

Oncology TypeHematologic (Lymphoma/CLL)
Drug Class / MechanismBTK Inhibitor
No Image
Description

Acalabrutinib is classified as a BTK Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy
Oncology TypeHematologic (Lymphoma/CLL)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3